Pfizer vaccine faces tougher production, global distribution challenges

*The vaccine faces logistical challenges as regards its production and distribution around the world since it must be kept at extremely cold temperatures: Report

Isola Moses | ConsumerConnect

Following the global euphoria that has greeted the feat as Pfizer reported final results showing that its two-shot vaccine was 95 percent effective against the virus, having  completed vaccine clinical trials, the drugmaker  yet may be facing logistical issues.

ConsumerConnect reports the company has stated there were 10 severe cases of COVID-19 observed in the trial, with nine of the cases occurring in the placebo group and one in the group that received the vaccine.

The group monitoring data said it found no serious side effects.

The Pfizer and Moderna vaccines are similar, and so far have achieved similar results, though Moderna has yet to complete its trial, according to report.

However, the Pfizer vaccine now faces tougher logistical challenges as regards production and distribution challenges, since it must be kept at extremely cold temperatures.

In terms of the vaccine reality check, it was gathered that since the results of their clinical trials are out, there is optimism due to impressive results from Pfizer’s and Moderna’s COVID-19 vaccine trials respectively.

In spite of this positive development, the company (Pfizer) partnering with Moderna to actually produce the vaccine has some sobering observations.

Swiss drugmaker Lonza says there are “big challenges” in producing the Moderna vaccine at scale and distributing it around the world.

Albert Baehny, Company Chairman, told CNBC that his company will have to greatly expand to meet the need.

Baehny said: “We can only produce more than 500 million doses a year if we install additional manufacturing lines.

“So, it is clear that we need additional investments in installation if we want to produce more than 500 million (per year) in the future.”

Kindly Share This Story